Industry landscapes
The companies, capital and talent shaping life sciences in San Diego. Find the leaders. Understand the segments. See where the activity is.
An industry ecosystem,
measured in context.
24 featured companies from the funding, hiring, revenue and team-size leaderboards.
Locked revenue figures are available in Radar; the eight company financial previews stay the same throughout this page. A dash means the figure is outside these featured lists. Revenue years vary by company; the figures are not a like-for-like revenue comparison. Compare annual accounts ↗
Recently founded means a recorded 2023–2026 founding year and no recorded parent, acquirer or public-company status. These companies are not labelled startups without that separate classification.
Explore classified startups in Radar ↗A few useful ratios bring the size of this ecosystem into perspective.
69 of 933 tracked companies have open roles.
500 of 933 tracked companies have a recorded round.
Share of disclosed capital received by the three largest recorded recipients.
Midpoint of 1,121 rounds with a disclosed amount.
Scale is concentrated. Opportunity is broader. The three largest funding recipients hold 10.7% of disclosed capital, while 46.4% of tracked companies have no recorded funding round.
Explore the segments →Recorded company formation and disclosed funding across the complete annual series shown.
Sum of recorded funding rounds · USD
| Year | Funding (USD) | Founded | Raising |
|---|---|---|---|
| 2016 | $1.8B | 44 | 85 |
| 2017 | $1.7B | 57 | 85 |
| 2018 | $3.2B | 49 | 96 |
| 2019 | $2.75B | 41 | 102 |
| 2020 | $4.82B | 39 | 97 |
| 2021 | $3.27B | 38 | 101 |
| 2022 | $2.81B | 13 | 69 |
| 2023 | $2.01B | 17 | 74 |
| 2024 | $3.95B | 13 | 71 |
| 2025 | $1.82B | 1 | 78 |
Share of all disclosed company funding.
1,214 recorded rounds since 2016
Recorded participation in life sciences company rounds since 2016.
Backed by Frazier Life Sciences and Novartis Venture Fund and others.
Backed by Deerfield and Longwood Fund and others.
Backed by .
Backed by Venrock and RA Capital Management and others.
Backed by Insight Partners and Felicis Ventures and others.
Backed by PanaceaCapital.
Backed by .
Backed by .
Backed by Venrock and RA Capital Management and others.
Backed by Vickers Venture Partners and Starling Group.
Backed by Arch Venture Partners and Orbimed and others.
Backed by New Enterprise Associates and Deep Track Capital and others.
Backed by Venrock and Fairmont and others.
Backed by Wellington and Samsung and others.
Backed by Janus Henderson Investors and Logos and others.
Backed by T. Rowe Price and Adage Capital Management and others.
Backed by Hillhouse and Invus and others.
Backed by General Electric and Celgene and others.
Annual accounts for reporting companies linked to this landscape, on like-for-like currency and reporting bases.
Display conversions use the dated reference rates above. Where a verified rate is unavailable, figures retain their source currency. Each reporting cohort keeps its currency and accounting basis separate.
FY2025 · annual statements grouped by reported fiscal year; exact entity periods remain on preview rows · 23 reporting entities from 68 eligible matches.
Sum of reporting-entity revenue; not San Diego market sales.
Combined result for the same cohort.
Combined net income ÷ combined revenue.
The middle covered reporting entity.
7 of 23 covered entities.
Share of covered revenue from the five largest entities.
Reported cohort totals by year; coverage is stated for every period.
Bar height shows revenue. Changes in coverage can affect totals.
FY2025 · 23 reporting entities
Up to eight fixed company previews show financial amounts. Search and sort the wider company list, then continue in Radar.
| Company / reporting entity | Revenue | Net profit / loss | Net margin | Revenue growth | Total assets |
|---|---|---|---|---|---|
| ResMed ↗943819 | $5,146.3m | $1,400.7m | +27.2% | — | — |
| Dexcom ↗1093557 | $4,662.0m | $836.3m | +17.9% | — | — |
| Neurocrine ↗914475 | $2,860.5m | $478.6m | +16.7% | — | — |
| Halozyme ↗1159036 | $1,396.6m | $316.9m | +22.7% | — | — |
| Acadia ↗1070494 | $1,071.5m | $391.0m | +36.5% | — | — |
| Tandem Diabetes ↗1438133 | $1,014.7m | $-204.7m | -20.2% | — | — |
| ATEC Spine ↗1350653 | $764.2m | $-143.4m | -18.8% | — | — |
| Crinetics ↗1658247 | $7.7m | $-465.3m | -6046.2% | — | — |
Explore full company accounts and filings.
Choose “View accounts” to inspect an available company preview.
Each pair uses the same year, currency and reporting basis. Cohort overlap is disclosed.
| Industry | Covered / eligible | Revenue total | Median revenue | Net profit / loss | Aggregate margin | Profitable share | Overlap |
|---|
Available-account cohorts are not estimates of whole industries. Overlapping entities can occur in more than one cohort; do not add cohort totals.
Filed annual accounts for exact designated national identifiers. Every aggregate and peer pair uses one fiscal year, source currency and reporting basis; periods, coverage and overlap are explicit; 2026 partials are excluded.
The same up to eight reporting entities remain open across years, filters and sorts. Other company figures are available in Radar.
Source currencies and accounting bases stay separate. Missing accounts are excluded rather than treated as zero. Exact reporting periods appear on company previews. Annual totals can change with coverage and do not measure growth of a fixed company cohort.
How the San Diego companies on this page show up online: the sites people visit, the apps they install, and how often those apps ship.
17 of these companies (1.8%) publish at least one Android app — 55 apps in all, carrying 11.4M installs between them.
| App | Installs | Rating | Store category |
|---|---|---|---|
| myAir™ by ResmedResMed | 4.3M | 4.2 | Medical |
| Dexcom G7Dexcom | 1.9M | 3.2 | Health & Fitness |
| Dexcom ClarityDexcom | 1.7M | 3.9 | Health & Fitness |
| Dexcom G6Dexcom | 1.1M | 3 | Medical |
| AirMini™ by ResMedResMed | 413.2K | 2.3 | Medical |
| Dexcom ONE+Dexcom | 220.6K | — | Medical |
| Tandem t:slim® mobile appTandem Diabetes | 199.7K | 1.8 | Health & Fitness |
| t:simulator™ AppTandem Diabetes | 199.3K | 4 | Medical |
| Dexcom FollowDexcom | 172K | 2.4 | Medical |
| Dexcom G6 mmol/L DXCM1Dexcom | 131.1K | — | Health & Fitness |
Installs are lifetime totals to date at the June 2026 store reading — a measure of reach, not of people using an app today.
The busiest app inside each of this page’s own segments, with the quarterly release trend behind it (2023Q1–2026Q1).
| Segment | Apps | Installs | Leading app | Release trend |
|---|---|---|---|---|
| Disease Self Management | 27 | 10.9M | myAir™ by Resmed 4.3M | |
| Diabetes | 27 | 6.5M | Dexcom G7 1.9M | |
| Wearable Technology | 24 | 6.1M | Dexcom Clarity 1.7M | |
| Sleep Medicine | 4 | 4.8M | AirMini™ by ResMed 413.2K | |
| Pulmonology | 3 | 4.8M | myAir™ Asia by Resmed™ 123K | |
| Genomics | 4 | 92.6K | iMolview Lite 47.1K | |
| Life Sciences Tech | 15 | 64.9K | iMolview 7.4K | |
| Healthcare It | 8 | 50.8K | Vision Training & Eye Exercise 49.9K |
A company can carry several segment tags, so these rows overlap and should not be added together. Trend lines are zero-based and share one quarter grid, so a flat line is a quiet segment, not a missing one.
New apps published, beside apps whose most recent update landed in that quarter — the second bar is how much of the shelf is still being maintained.
Darker bars are new releases, lighter bars apps updated. 37 of 55 apps carry a release date. The series ends at 2026Q1, the last quarter that closed before the June 2026 reading.
Explore the segments behind the headline numbers.
Rank segments by scale, hiring or disclosed funding.
Companies can sit in several segments. Counts and funding overlap.
The largest measured segment in this report snapshot.
58 companies hiring · $32.14B disclosed funding
Explore in RadarCommon revenue models; a company can use more than one.
Recorded corporate activity linked to companies in this landscape.
UCB SA agreed to pay $2 billion up front to acquire bispecific T-cell engager (TCE)-maker Candid Therapeutics Inc. and lead BCMA/CD3 TCE asset cizutamig (CND-106), continuing big pharma’s spree for China-made autoimmune assets in 2026.
the gross proceeds to the Company from the Offering are estimated to be approximately $3.4 million before deducting placement agent fees and other offering expenses.
Neomorph Raises $100M Series B Funding for Molecular Glue Oncology R&D
Neurocrine Biosciences, Inc. (NASDAQ: NBIX) has agreed to acquire Soleno Therapeutics, Inc. (NASDAQ: SLNO) for $53.00 per share in cash, valuing the target at about $2.9 billion.
Announced a private placement to raise approximately $11.0 million in gross proceeds (3,188,407 shares and warrants), with warrants exercisable at $3.20 and potential additional proceeds if exercised — provides near-term cash for working capital and to repay bridge debt.
SeaX Ventures, a venture capital firm focusing on Southeast Asia, will continue investing in RyboDyn, a biotechnology startup based in the United States, as part of the latter’s $10 million seed funding round.
Condor Software has now raised a total of $29.5M in total equity funding and is backed by 645 Ventures, Bramalea Partners, Felicis, Insight Partners, Pamir Ventures, Prebys Ventures, and SNR.vc.
Calidi Biotherapeutics, Inc. (NYSE AMERICAN: CLDI) announced the pricing of its underwritten public offering of 10,519,631 units.
American Assets Inc. bought a new stake in ARS Pharmaceuticals, Inc. (NASDAQ:SPRY – Free Report) during the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission.
San Diego-based clinical-stage biotechnology company Mirador Therapeutics Inc. closed a $250 million Series B financing in the third quarter of 2025.
Top 10 categories among 1,555 recorded events in the 24-month window.
59 companies with recorded IPO activity
Follow-on Offering · NYSE American5 reports
Follow-on Offering · Nasdaq3 reports
IPO activity1 reports
IPO · NASDAQ7 reports
Follow-on Offering · NASDAQ3 reports
IPO · NASDAQ7 reports
IPO activity · Nasdaq1 reports
IPO · NASDAQ1 reports
48 tracked people moves
Appointment Independent Director
Appointment Chief Executive Officer
Retirement Previously Director
Retirement Previously Director
Retirement Previously Director
Appointment Chief Executive Officer
Promotion Chief Technical Operations Officer
Appointment Interim Chief Financial Officer
28 recorded customer wins
Customer: takeda
Customer: invitrogenGenomics
Customer: Mundipharma InternationalHealthcare
Customer: Molecular Profiling Institute Inc.*
Customer: Taisho Pharmaceuticals Ltd.
Customer: F. Hoffmann-La Roche Ltd.Biopharmaceutical
14 companies with reported reductions
Scale not stated rolesfunding
65 rolesbusiness downturn
22 rolescash runway
52 rolespost-acquisition
305 rolesmanufacturing relocation
50 rolescost reduction
57 recorded events
IND clearance granted
approved for seizures associated with Dravet syndrome and Lennox-Gastaut syndrome
approved 180‑day extension for complianceNasdaq Stock Market LLC
grant approved
28 tracked suits
Anticipatory breach and declaratory judgment dispute over license agreementCivil · Ongoing
Federal Securities Laws violationCivil · Filed
Reported company results in the recorded window.
Median across 217 reported growth observations; companies may contribute multiple periods.
Company-linked deal reports; status is preserved as recorded.
| Acquirer → target | Status | Date | Value / context |
|---|---|---|---|
| merck sharp & dohme→Artiva ↗ | Terminated | 2026-06-25 | $1.9B |
| Candid Therapeutics→rallybio | Terminated | 2026-05-04 | Not stated in snapshot |
| UCB SA→Candid Therapeutics ↗ | Announced | 2026-05-04 | $2.0B |
| merck→Cidara Therapeutics ↗ | Completed | 2026-04-28 | $9.2B |
| Neurocrine→soleno therapeutics | Announced | 2026-04-08 | $2.9B |
| rallybio→Candid Therapeutics ↗ | Announced | 2026-03-03 | Not stated in snapshot |
A discussion or rumour is not a completed transaction. An unstated value is not zero.
1,156 postings in the preceding 12 months. The full 1,556-posting snapshot covers 66 employers.
29 tracked postings mention remote work.
660 postings specify a level.
Top skills across 1,556 tracked postings in the available jobs snapshot.
Median across 170 postings with pay data, expressed in USD.
Advertised posting medians do not describe all employees or roles.
| Company | Open roles |
|---|---|
| ResMed ↗ | 12 |
| Dexcom ↗ | 11 |
| Cassia ↗ | 10 |
| ATEC Spine ↗ | 9 |
| CARLSMED ↗ | 9 |
| Travere Therapeutics ↗ | 7 |
| ADARx Pharmaceuticals ↗ | 6 |
| Faro Health ↗ | 6 |
| Company | Employees |
|---|---|
| carefusion ↗ | 14,000 |
| ResMed ↗ | 10,140 |
| Dexcom ↗ | 9,600 |
| Illumina ↗ | 5,548 |
| Tandem Diabetes ↗ | 1,922 |
| eBioscience ↗ | 1,001 |
| Sorrento Therapeutics ↗ | 949 |
| Idun Pharmaceuticals ↗ | 853 |
651 founders and chief executives across 479 companies.
Ex-CFO Biosensors International. Brigham Young University BS 1983
Ex-Ablaze Pharmaceuticals, RayzeBio · Massachusetts Institute of Technology BS 1996, University of California…
Ex-Prometheus Biosciences, Salix Pharmaceuticals. W. P. Carey School of Business – Arizona State University BSc, Azusa Pacific University MBA 2008
Ex-Illumina, Pacific Biosciences, Sunesis Pharmaceuticals, Chiron. Nankai University 1992, University of California, Los Angeles PhD 1997
Sling Therapeutics, ex-Tocagen, ex-Vital Therapies, University of Windsor, 1983
UCLA Anderson School of Management MBA, UC Los Angeles PhD
Tandem Diabetes Care, ex-Rapiscan Systems, ex-Volcano, Boston University - School of Management, 1991
Ex-Arthur D Little, Sanofi Genzyme, BHP Billiton. UNSW BE 1994, MIT MS 1998
Radionetics Oncology, San Diego Entrepreneurs Exchange, ex-Sciencemedia, Biosym Technologies. UC San Diego PHD 1992
Heron Therapeutics, ex-Synageva BioPharma, Furiex Pharmaceuticals, Heron Therapeutics. Southern Nazarene University BS 1983…
Capstan Therapeutics, Recludix Therapeutics, Leal Therapeutics, Passage Bio, ex-Turning Point Therapeutics. Tufts University School of Medicine MD
Nektar Therapeutics, FivePrime Therapeutics, Chiron Corporation, Lawrence Berkeley National Laboratory. Carnegie-Mellon University BS…
104 profiles with education records.
5 profiles with prior-work records.
Profiles cover recorded founders and leaders; contact details remain in Radar.
5,012 articles in the measured 12-month window.
Life Sciences coverage tagged San Diego · articles per complete quarter
| Quarter | Articles |
|---|---|
| 2021Q2 | 1,395 |
| 2021Q3 | 1,553 |
| 2021Q4 | 1,250 |
| 2022Q1 | 1,730 |
| 2022Q2 | 1,524 |
| 2022Q3 | 1,253 |
| 2022Q4 | 1,344 |
| 2023Q1 | 1,437 |
| 2023Q2 | 2,168 |
| 2023Q3 | 1,326 |
| 2023Q4 | 2,462 |
| 2024Q1 | 2,065 |
| 2024Q2 | 2,543 |
| 2024Q3 | 1,522 |
| 2024Q4 | 1,888 |
| 2025Q1 | 12,244 |
| 2025Q2 | 1,108 |
| 2025Q3 | 872 |
| 2025Q4 | 1,367 |
| 2026Q1 | 1,638 |
Article volume measures coverage, not market sales.
2,394 recorded company events across 191 companies; percentages use that event total.
Life Sciences coverage tagged San Diego · ranked by full-period article count.
Recent and prior counts use the source comparison windows.
United States comparison coverage
| Keyword | Recent | Prior | Change |
|---|---|---|---|
| vaccine candidates | 3,157 | 898 | 252% |
| vaccine trials | 2,962 | 904 | 228% |
| vaccination campaigns | 2,752 | 555 | 396% |
| vaccine immunogenicity | 2,473 | 668 | 270% |
| mass vaccination sites | 2,021 | 272 | 643% |
| vaccination coverage | 1,516 | 202 | 650% |
| vaccine effectiveness study | 1,400 | 251 | 458% |
| angel investors | 1,344 | 590 | 128% |
| covid-19 vaccine development | 1,335 | 238 | 461% |
| pandemic vaccine stockpiling | 1,294 | 242 | 435% |
| investigational new vaccine | 451 | 1,069 | -58% |
| cell-based therapies | 619 | 1,059 | -42% |
| viral vector vaccines | 684 | 1,048 | -35% |
| cancer biomarkers | 670 | 1,040 | -36% |
| diagnostic biotechnology | 570 | 948 | -40% |
United States comparison coverage
core inflation rate, inflation outlook, inflation breakdown
52.8% critical · 34.6% positiveangel investors, vaccine candidates, vaccine trials
49.1% critical · 55.2% positivegdp acceleration, gdp growth rate, economic output growth
49.7% critical · 39.6% positiveLife Sciences coverage tagged San Diego. Topic labels describe recorded classifications and can include broad context.
6,260 papers in the recorded india scope.
Tone counts: 5,526 positive · 456 neutral · 278 negative.
Landmark: The International Scientific Association for Probiotics and Prebiotics consensus statement on the scope and appropriate use of the term prob
Landmark: Genomic responses in mouse models poorly mimic human inflammatory diseases
Landmark: U1 snRNP regulates cancer cell migration and invasion in vitro
Common problems researchers identify · 0118.4% of this theme group
Researchers highlight limitations in enzyme use, biofilm control, and nanotech integration for scalable biochemical production.
Biochemical engineering (18) · Synthetic biology (12) · Biomanufacturing (8) · Nanotechnology (9)
Microbial Enzymes: Tools for Biotechnological Processes
Medical biofilms
| Year | Share index |
|---|---|
| 2022 | 67.9 |
| 2023 | 70.3 |
| 2024 | 84.4 |
| 2025 | 67.1 |
Common problems researchers identify · 0215.7% of this theme group
Studies point to rising outbreaks, toxin exposure, and gaps in surveillance for safe food supply.
Public health (15) · Mycotoxin (8) · Disease (12) · Contamination (8)
The growing burden of foodborne outbreaks due to contaminated fresh produce: risks and opportunities
A review of Listeria monocytogenes: An update on outbreaks, virulence, dose-response, ecology, and risk assessments
| Year | Share index |
|---|---|
| 2022 | 301.0 |
| 2023 | 265.8 |
| 2024 | 276.2 |
| 2025 | 304.0 |
Common problems researchers identify · 0315.5% of this theme group
Authors discuss difficulties in interpreting mutation patterns, methylation signals, and metabolic imaging for tumor profiling.
Mutation (7) · Cancer (9) · DNA methylation (5) · Gene (8)
Analysis of Cancer Metabolism by Imaging Hyperpolarized Nuclei: Prospects for Translation to Clinical Research
Examination of the specificity of DNA methylation profiling techniques towards 5-methylcytosine and 5-hydroxymethylcytosine
| Year | Share index |
|---|---|
| 2022 | 974.1 |
| 2023 | 1199.2 |
| 2024 | 866.8 |
| 2025 | 797.1 |
Common problems researchers identify · 0415.2% of this theme group
Papers note obstacles in engineering stress‑tolerant crops and integrating hormonal pathways for resilient farming.
Agriculture (33) · Abiotic stress (10) · Abiotic component (12) · Biotechnology (20)
Genetic Engineering for Modern Agriculture: Challenges and Perspectives
Phytohormones and their metabolic engineering for abiotic stress tolerance in crop plants
| Year | Share index |
|---|---|
| 2022 | 1472.5 |
| 2023 | 1503.8 |
| 2024 | 1656.9 |
| 2025 | 1839.0 |
Common problems researchers identify · 0514.7% of this theme group
Research reveals challenges in biofortification, micronutrient delivery, and consistent fermentation outcomes.
Micronutrient (9) · Production (13) · Nutrient (10) · Food science (7)
Improving nutrition through biofortification: A review of evidence from HarvestPlus, 2003 through 2016
Food fermentations: Microorganisms with technological beneficial use
| Year | Share index |
|---|---|
| 2022 | 120.6 |
| 2023 | 117.1 |
| 2024 | 113.1 |
| 2025 | 122.2 |
Common problems researchers identify · 0611.1% of this theme group
Authors emphasize the spread of resistant strains and limited effectiveness of current antimicrobial strategies.
Antibiotic resistance (49) · Antimicrobial (31) · Antibiotics (22) · Drug resistance (8)
An overview of the antimicrobial resistance mechanisms of bacteria
The global threat of antimicrobial resistance: science for intervention
| Year | Share index |
|---|---|
| 2022 | 886.3 |
| 2023 | 838.0 |
| 2024 | 911.9 |
| 2025 | 963.5 |
Common problems researchers identify · 079.5% of this theme group
Studies identify growing resistance in pests and the need for integrated control approaches.
Resistance (14) · Insecticide resistance (5) · Vector (5) · Integrated pest management (5)
Insecticide Resistance in Mosquitoes: Impact, Mechanisms, and Research Directions
Innate Immunity in Plants: An Arms Race Between Pattern Recognition Receptors in Plants and Effectors in Microbial Pathogens
| Year | Share index |
|---|---|
| 2022 | 3.4 |
| 2023 | 3.1 |
| 2024 | 4.4 |
| 2025 | 4.3 |
Cautions · 0124.6% of this theme group
Researchers urge caution interpreting repair pathway data due to assay variability and mutation complexity.
DNA repair (7) · DNA polymerase (6) · DNA damage (7) · Mutation (9)
Examining the link between chromosomal instability and aneuploidy in human cells
Comparative analysis of microRNA expression in serum and plasma in patients screened for BRCA1 or BRCA2 mutations
| Year | Share index |
|---|---|
| 2022 | 101.2 |
| 2023 | 139.0 |
| 2024 | 91.9 |
| 2025 | 79.2 |
Cautions · 0218.1% of this theme group
Works caution about off‑target effects and infection risk when manipulating antibodies and immune cells in vivo.
Antibody (9) · In vivo (8) · Peripheral blood mononuclear cell (4) · Immune system (5)
Selective B-cell subset depletion underlies increased infection risk in patients with MM treated with anti-BCMA vs anti-GPRC5D bsAbs
T cell responses towards PINK1 and ⍺-synuclein are elevated in prodromal Parkinson's disease - Fluorospot data
| Year | Share index |
|---|---|
| 2022 | 543.7 |
| 2023 | 602.0 |
| 2024 | 448.8 |
| 2025 | 441.1 |
Cautions · 0314.4% of this theme group
Papers warn of potential hazards from novel ingredients, nanomaterials, and sugar‑related health impacts.
Food safety (6) · Raw material (4) · Health benefits (4) · Sugar (3)
Caffeine (1, 3, 7‐trimethylxanthine) in Foods: A Comprehensive Review on Consumption, Functionality, Safety, and Regulatory Matters
Soybean susceptibility to manufactured nanomaterials with evidence for food quality and soil fertility interruption
| Year | Share index |
|---|---|
| 2022 | 122.8 |
| 2023 | 120.4 |
| 2024 | 118.6 |
| 2025 | 154.1 |
Cautions · 0411.6% of this theme group
Authors highlight uncertainties in feed additives affecting animal health, productivity, and methane emissions.
Dairy cattle (6) · Production (6) · Nutrient (6) · Beef cattle (5)
Impact of tannin-based additives on animal performance and enteric methane emissions in dairy and beef cattle: A meta-analysis
The effects of injectable trace mineral solutions on beef cattle performance and health during preconditioning and feedlot receiving: a syst
| Year | Share index |
|---|---|
| 2022 | 126.8 |
| 2023 | 122.4 |
| 2024 | 118.5 |
| 2025 | 129.2 |
Cautions · 0510.8% of this theme group
Research points to challenges in translating genomic markers into reliable trait improvement across species.
Gene (10) · Genomic selection (5) · Selection (6) · Trait (4)
Genomic Selection for Crop Improvement
Genomic selection in plant breeding: from theory to practice
| Year | Share index |
|---|---|
| 2022 | 2367.9 |
| 2023 | 2351.5 |
| 2024 | 2081.1 |
| 2025 | 1566.0 |
Cautions · 0610.5% of this theme group
Studies caution about efficacy and ecological impacts of biological control and pesticide resistance management.
PEST analysis (9) · Agriculture (7) · Pest control (3) · Integrated pest management (3)
The use of fungal entomopathogens as endophytes in biological control: a review
Insecticide Control of Vector-Borne Diseases: When Is Insecticide Resistance a Problem?
| Year | Share index |
|---|---|
| 2022 | 1443.5 |
| 2023 | 1484.3 |
| 2024 | 1642.9 |
| 2025 | 1827.1 |
Cautions · 079.9% of this theme group
Authors stress the need to monitor antimicrobial practices to prevent resistance transfer between animals and humans.
Antibiotic resistance (12) · Antibiotics (9) · Antimicrobial (6) · Bacteria (5)
Multidrug evolutionary strategies to reverse antibiotic resistance
Impact of Antibiotic Use in Adult Dairy Cows on Antimicrobial Resistance of Veterinary and Human Pathogens: A Comprehensive Review
| Year | Share index |
|---|---|
| 2022 | 886.3 |
| 2023 | 838.0 |
| 2024 | 911.9 |
| 2025 | 963.5 |
Opportunities · 0119.6% of this theme group
Emerging work explores beneficial microbes and their metabolites for improving human and animal health.
Antimicrobial (64) · Fermentation (55) · Bacteria (52) · Antibiotic resistance (37)
Probiotics, their health benefits and applications for developing healthier foods: a review
Postbiotics: Multifunctional Microbial Products Transforming Animal Health and Performance
| Year | Share index |
|---|---|
| 2022 | 2406.7 |
| 2023 | 2240.7 |
| 2024 | 2316.1 |
| 2025 | 1955.8 |
Opportunities · 0219.3% of this theme group
Research uncovers new ways to adjust gene expression and apoptosis pathways for disease treatment.
Apoptosis (37) · Downregulation and upregulation (57) · Gene knockdown (46) · Mutant (48)
PCBP1 binding to single-stranded poly-cytosine motifs enhances cGAS sensing and impairs breast cancer development
Modulation of ossification and inflammatory pathways during dexamethasone-induced <i>in vitro</i> osteogenesis
| Year | Share index |
|---|---|
| 2022 | 364.0 |
| 2023 | 394.7 |
| 2024 | 257.4 |
| 2025 | 261.8 |
Opportunities · 0313.2% of this theme group
Studies advance antibody and microvesicle strategies to direct T‑cell responses against cancers.
Cell culture (77) · T cell (54) · Antigen (49) · Cell (62)
CS1, a Potential New Therapeutic Antibody Target for the Treatment of Multiple Myeloma
Tumor-Derived Microvesicles Promote Regulatory T Cell Expansion and Induce Apoptosis in Tumor-Reactive Activated CD8+ T Lymphocytes
| Year | Share index |
|---|---|
| 2022 | 289.3 |
| 2023 | 336.1 |
| 2024 | 224.8 |
| 2025 | 204.1 |
Opportunities · 0412.8% of this theme group
Papers present novel approaches to modify methylation and repair mechanisms for therapeutic benefit.
DNA repair (65) · DNA damage (68) · DNA methylation (58) · DNA replication (34)
Convergent DNA methylation abnormalities at enhancers and bivalent promoters in human growth disorders
MacroH2A-Mediated Gene Repression through Nucleosome Compaction and Remodeling Inhibition
| Year | Share index |
|---|---|
| 2022 | 224.2 |
| 2023 | 281.6 |
| 2024 | 196.5 |
| 2025 | 158.4 |
Opportunities · 0512.2% of this theme group
Works develop fluorescent and nanoparticle probes for real‑time tracking of biological processes.
In vivo (142) · Fluorescence (41) · Molecular imaging (28) · Nanotechnology (33)
Activatable cell penetrating peptides linked to nanoparticles as dual probes for in vivo fluorescence and MR imaging of proteases
Recognition, Neutralization, and Clearance of Target Peptides in the Bloodstream of Living Mice by Molecularly Imprinted Polymer Nanoparticl
| Year | Share index |
|---|---|
| 2022 | 480.4 |
| 2023 | 520.5 |
| 2024 | 397.5 |
| 2025 | 406.8 |
Opportunities · 0611.7% of this theme group
Research leverages sequencing and germplasm resources to accelerate breeding of resilient varieties.
Germplasm (37) · Selection (42) · Genetic diversity (28) · Trait (28)
Genotyping‐by‐Sequencing for Plant Breeding and Genetics
Harvesting the Promising Fruits of Genomics: Applying Genome Sequencing Technologies to Crop Breeding
| Year | Share index |
|---|---|
| 2022 | 56.0 |
| 2023 | 51.4 |
| 2024 | 46.1 |
| 2025 | 53.1 |
Opportunities · 0711.3% of this theme group
Studies reveal how mRNA and microRNA changes influence cell fate and disease pathways.
Messenger RNA (103) · microRNA (61) · Transcription (65) · RNA polymerase II (34)
m <sup>6</sup> A mRNA methylation facilitates resolution of naïve pluripotency toward differentiation
Microrna-Dependent Regulation of Dna Methyltransferase-1 and Tumor Suppressor Gene Expression by Interleukin-6 in Human Malignant Cholangioc
| Year | Share index |
|---|---|
| 2022 | 229.2 |
| 2023 | 195.8 |
| 2024 | 157.3 |
| 2025 | 136.5 |
Orientation shares compared with 25,000 papers in the reference sample.
| Research orientation | This field | Reference sample |
|---|---|---|
| Breakthrough | 32.6% | 26.3% |
| Promising | 31.0% | 37.6% |
| Descriptive | 17.5% | 17.3% |
| Problem-identifying | 9.1% | 9.6% |
| Cautionary | 5.8% | 4.6% |
| Comparative | 2.8% | 3.8% |
| Critical | 1.3% | 0.9% |
Counts and shares refer to the stated research pool. A low count describes how much of that research is recorded here, not the absence of a real-world concern.
| Concern / example paper | Papers | Share | Raised as a problem | Worldwide share |
|---|---|---|---|---|
| Privacy & surveillanceSARS-CoV-2 wastewater genomic surveillance: approaches, challenges, and opportunities | 18 | 0.3% | 2 (11.1%) | 0.21% |
| Hardware, e-waste & supply chainFate and Transport of Antibiotic Residues and Antibiotic Resistance Genes following Land Application of Manure Waste | 4 | 0.07% | 1 (25.0%) | 0.15% |
| Bias & fairnessNot All Allies Are Welcome: Partner Discrimination in Legume–Rhizobium Symbiosis | 3 | 0.05% | 1 (33.3%) | 0.03% |
| Safety & misusePublic perceptions and information sources on genetically modified organisms in Kenya | 1 | 0.02% | 1 (100.0%) | 0.01% |
| Energy & datacenter footprint | 0 | 0.0% | 0 (%) | 0.0% |
| Water use | 0 | 0.0% | 0 (%) | 0.0% |
| Carbon & emissions of compute | 0 | 0.0% | 0 (%) | 0.0% |
| Labour & data work | 0 | 0.0% | 0 (%) | 0.0% |
| Concentration of compute power | 0 | 0.0% | 0 (%) | 0.0% |
Research orientation and citation rankings describe the covered collection. Its recorded publication dates do not support an overall publication-volume trend.
Institution and researcher rankings use citations to their covered work. Research scope: United States. This may be broader than the company geography.
Clear definitions for making better comparisons.
It measures the tracked company ecosystem, recorded funding, hiring and other available evidence. It is not a market-size estimate.
No. A company can belong to several segments, so segment counts and funding can overlap.
A dash or unavailable panel means the current reviewed source snapshot does not support that figure.
Company ecosystem snapshot: 31 August 2026. Funding is recorded in USD; filed accounts retain their stated currency and reporting basis. Each section identifies its own coverage. The news and research behind these sections is explorable in Prism.
Canonical landscape ↗